6NO9 | pdb_00006no9

PIM1 in complex with Cpd16 (5-amino-N-(5-((4R,5R)-4-amino-5-fluoroazepan-1-yl)-1-methyl-1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.71 Å
  • R-Value Free: 
    0.205 (Depositor), 0.208 (DCC) 
  • R-Value Work: 
    0.168 (Depositor), 0.169 (DCC) 
  • R-Value Observed: 
    0.170 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6NO9

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.

Wang, X.Blackaby, W.Allen, V.Chan, G.K.Y.Chang, J.H.Chiang, P.C.Diene, C.Drummond, J.Do, S.Fan, E.Harstad, E.B.Hodges, A.Hu, H.Jia, W.Kofie, W.Kolesnikov, A.Lyssikatos, J.P.Ly, J.Matteucci, M.Moffat, J.G.Munugalavadla, V.Murray, J.Nash, D.Noland, C.L.Del Rosario, G.Ross, L.Rouse, C.Sharpe, A.Slaga, D.Sun, M.Tsui, V.Wallweber, H.Yu, S.F.Ebens, A.J.

(2019) J Med Chem 62: 2140-2153

  • DOI: https://doi.org/10.1021/acs.jmedchem.8b01857
  • Primary Citation Related Structures: 
    6NO9

  • PubMed Abstract: 

    Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.


  • Organizational Affiliation
    • Genentech, Inc. , 1 DNA Way , South San Francisco , California 94080 , United States.

Macromolecule Content 

  • Total Structure Weight: 32.27 kDa 
  • Atom Count: 2,405 
  • Modeled Residue Count: 273 
  • Deposited Residue Count: 273 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Serine/threonine-protein kinase pim-1273Homo sapiensMutation(s): 0 
Gene Names: PIM1
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for P11309 (Homo sapiens)
Explore P11309 
Go to UniProtKB:  P11309
PHAROS:  P11309
GTEx:  ENSG00000137193 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP11309
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.71 Å
  • R-Value Free:  0.205 (Depositor), 0.208 (DCC) 
  • R-Value Work:  0.168 (Depositor), 0.169 (DCC) 
  • R-Value Observed: 0.170 (Depositor) 
Space Group: P 65
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 96.632α = 90
b = 96.632β = 90
c = 80.703γ = 120
Software Package:
Software NamePurpose
XDSdata reduction
Aimlessdata scaling
PHENIXrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-02-27
    Type: Initial release
  • Version 1.1: 2019-03-13
    Changes: Data collection, Database references
  • Version 1.2: 2023-10-11
    Changes: Data collection, Database references, Refinement description